Related Experiment Video
Updated: Aug 9, 2025
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.1K
Clopidogrel Use in CYP2C19 Loss-of-Function Carriers With High Bleeding Risk After Percutaneous Coronary Intervention
Yuichi Sawayama1, Yukinori Tomita2, Soji Kohyama1
1Department of Cardiovascular Medicine, Shiga University of Medical Science.
Summary
For patients with high bleeding risk undergoing percutaneous coronary intervention, clopidogrel use in CYP2C19 loss-of-function carriers is linked to more ischemic events. This highlights risks associated with specific genetic profiles and antiplatelet therapy choices.
Area of Science:
- Cardiology
- Pharmacogenomics
- Interventional Cardiology
Background:
- The impact of clopidogrel in patients with high bleeding risk (HBR) and CYP2C19 loss-of-function (LOF) following percutaneous coronary intervention (PCI) remains unclear.
- CYP2C19 genetic variations affect clopidogrel metabolism and efficacy, posing potential risks in specific patient populations.
- High bleeding risk criteria, such as the Academic Research Consortium definition, identify patients susceptible to bleeding complications.
Purpose of the Study:
- To investigate the association between clopidogrel use in CYP2C19 LOF carriers with HBR and adverse clinical outcomes after PCI.
- To compare ischemic and bleeding events between patients with decreased P2Y12 inhibitor action versus retained action.
Main Methods:
- Retrospective observational study of 618 patients undergoing PCI with available CYP2C19 polymorphism data.
- Patients with HBR were stratified into groups based on P2Y12 inhibitor action: decreased (clopidogrel in CYP2C19 LOF carriers) and retained.
- Clinical outcomes at 1 year were compared using inverse probability-weighted Cox proportional hazard regression.
Main Results:
- The primary ischemic outcome (cardiovascular death, myocardial infarction, ischemic stroke) was significantly higher in the decreased action group (10.2%) compared to the retained group (3.0%).
- No significant difference was observed in the primary bleeding outcome (BARC 3 or 5) between the decreased (3.4%) and retained (6.9%) groups.
- No significant interactions were found between treatment groups and HBR status for either ischemic or bleeding outcomes.
Conclusions:
- In patients with high bleeding risk, clopidogrel use in CYP2C19 loss-of-function carriers is significantly associated with an increased risk of ischemic events post-PCI.
- These findings underscore the importance of considering pharmacogenetic profiles in antiplatelet therapy selection for HBR patients undergoing PCI.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
576
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
576
01:27Peripheral Artery Disease III: Interprofessional Care
17
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
17
01:27Coronary Artery Disease V: Interprofessional Care
20
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
20
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
238
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
238
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
809
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
809
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
225
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
225